HEXO Corp (HEXO.CA) Stock Fundamental Analysis
TSX:HEXO - Toronto Stock Exchange - CA4283044069 - Common Stock - Currency: CAD
We assign a fundamental rating of 1 out of 10 to HEXO. HEXO was compared to 35 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of HEXO have multiple concerns. HEXO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year HEXO has reported negative net income.
HEXO had a negative operating cash flow in the past year.
HEXO had negative earnings in each of the past 5 years.
In the past 5 years HEXO always reported negative operating cash flow.
1.2 Ratios
HEXO has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for HEXO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HEXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HEXO has been increased compared to 1 year ago.
The debt/assets ratio for HEXO has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -7.93, we must say that HEXO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.93, HEXO is doing worse than 76.09% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that HEXO is not too dependend on debt financing.
The Debt to Equity ratio of HEXO (0.01) is better than 80.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.93 |
ROIC/WACCN/A
WACC2.8%
2.3 Liquidity
HEXO has a Current Ratio of 0.41. This is a bad value and indicates that HEXO is not financially healthy enough and could expect problems in meeting its short term obligations.
HEXO's Current ratio of 0.41 is on the low side compared to the rest of the industry. HEXO is outperformed by 78.26% of its industry peers.
HEXO has a Quick Ratio of 0.41. This is a bad value and indicates that HEXO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.24, HEXO is doing worse than 76.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.41 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.82% over the past year.
The Revenue for HEXO has decreased by -47.74% in the past year. This is quite bad
Measured over the past years, HEXO shows a very strong growth in Revenue. The Revenue has been growing by 115.62% on average per year.
EPS 1Y (TTM)90.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.6%
Revenue 1Y (TTM)-47.74%
Revenue growth 3Y59%
Revenue growth 5Y115.62%
Sales Q2Q%-52.63%
3.2 Future
HEXO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.92% yearly.
HEXO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.44% yearly.
EPS Next Y99.88%
EPS Next 2Y41.35%
EPS Next 3Y25.96%
EPS Next 5Y18.92%
Revenue Next Year-42.24%
Revenue Next 2Y-21.51%
Revenue Next 3Y-9.95%
Revenue Next 5Y-5.44%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
HEXO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HEXO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HEXO's earnings are expected to grow with 25.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.35%
EPS Next 3Y25.96%
5. Dividend
5.1 Amount
No dividends for HEXO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:HEXO (6/26/2023, 7:00:00 PM)
0.88
+0.01 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.9%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap38.18M
Analysts46.67
Price Target1.64 (86.36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3004.62%
Min EPS beat(2)-5995.95%
Max EPS beat(2)-13.29%
EPS beat(4)1
Avg EPS beat(4)-1525.55%
Min EPS beat(4)-5995.95%
Max EPS beat(4)97.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-25.3%
Min Revenue beat(2)-34.46%
Max Revenue beat(2)-16.13%
Revenue beat(4)0
Avg Revenue beat(4)-16.54%
Min Revenue beat(4)-34.46%
Max Revenue beat(4)-5.76%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-27.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)76.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-25.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.27 | ||
| P/tB | 0.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-40.48
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS2.86
BVpS3.29
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 32.53% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.41 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | -7.93 |
F-Score3
WACC2.8%
ROIC/WACCN/A
Cap/Depr(3y)357.42%
Cap/Depr(5y)1584.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.6%
EPS Next Y99.88%
EPS Next 2Y41.35%
EPS Next 3Y25.96%
EPS Next 5Y18.92%
Revenue 1Y (TTM)-47.74%
Revenue growth 3Y59%
Revenue growth 5Y115.62%
Sales Q2Q%-52.63%
Revenue Next Year-42.24%
Revenue Next 2Y-21.51%
Revenue Next 3Y-9.95%
Revenue Next 5Y-5.44%
EBIT growth 1Y54.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.56%
EBIT Next 3Y26.3%
EBIT Next 5Y19.3%
FCF growth 1Y-17.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.11%
OCF growth 3YN/A
OCF growth 5YN/A